September 24, 2024 11:45 ET | Source: Transgene S.A. Transgene S.A.
2024 Half Year Financial Report
Attachment
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate at WCID
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
